Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure

Exclusion Criteria

• •Metformin treatment within the last 3 months
• •Known allergy to metformin or major side effects to metformin treatment
• •Acute myocardial infarction, unstable angina or revascularization \< 3 months at the time of randomization
• •Planned coronary revascularization
• •Significant, uncorrected cardiac valve disease
• •Cardiac arrest or life threatening ventricular arrhythmias within the last 3 months (unless treated with an ICD)
• •Atrial fibrillation with poorly controlled ventricular rate at rest (\> 100 beats/min)
• •Hypertrophic or restrictive cardiomyopathy, infiltrative or storage myocardial disease, active myocarditis, or pericardial disease.
• •Planned major surgery
• •Female patients who are pregnant, nursing, or of childbearing potential while not practicing effective chemical contraceptive methods (i.e. oral, implanted, injectable, or transdermal contraceptive hormones; intrauterine device)
• •Age \< 18 years
• •Current abuse of alcohol or drugs
• •Cancer, with a life-expectancy of less than 2 years
• •Stroke within the last 6 months
• •Liver disease with P-ALAT \>3 times upper normal limit (it is possible to repeat this measurement once within a month)
• •Significant comorbidity or issue that makes the patient unsuitable for participation as judged by the investigator
• •Participation in another study involving long-term medical intervention (participation in device studies is allowed)